| 证券代码 | ELGX.O |
| 证券名称 | 恩多勒吉克斯 |
| 证券类型 | 美股 |
| 上市场所 | 纳斯达克交易所 |
| 上市板块 | - |
| 发行方式 | - |
| 首发上市日 | 1996-06-20 |
| 首发价格(元) | - |
| 首发数量(股) | 0 |
| 首发募资额(元) | - |
| 首发主承销商 | - |
| 货币单位 | USD |
| 公司名称 | Endologix, Inc. |
| 注册地址 | 美国特拉华州 |
| 办公地址 | 2 Musick, Irvine, California, USA |
| 成立日期 | 1993-06 |
| 董事会主席 | Daniel Lemaitre |
| 公司属地 | United States 美国 |
| 公司网址 | www.endologix.com |
| 电话 | +1 (949) 595-7200 |
| 传真 | +1 (949) 699-9622 |
| 公司简介 | Endologix, Inc., founded in 1992, is singularly focused on providing innovative, minimally invasive technologies for aortic disorders. Their current product offering includes a variety of endovascular stent grafts for the treatment of abdominal aortic aneurysms (AAA) and are protected by more than 108 patents. Designed around key issues with challenging anatomies, difficult access and aneurysm sealing, Endologix products have been clinically proven in delivering positive patient outcomes. They are uniquely positioned to offer the most comprehensive product portfolio in AAA therapy. Deeply committed to addressing unmet needs in aortic therapies, Endologix continuously strives to bring ground-breaking and effective solutions to physicians and their patients. With a robust pipeline of best-in-class technology, their vision is to provide physicians with the best device for each patient; because when it comes to ensuring patient well being, they are never satisfied with the status quo. |